Ye Weiguo 4

What Happened Ye Weiguo, Chief Operating Officer of Gyre Therapeutics (GYRE), exercised vested stock options and immediately sold the resulting shares in open-market transactions. He exercised 19,575 options on June 4, 2026 (paying $0.75 per share) and sold those 19,575 shares at a weighted average price of $6.13 for proceeds of $119,995. On June 5, 2026 he exercised 15,401 options (paying $0.75 per share) and sold those 15,401 shares at a weighted average price of $6.40 for proceeds of $98,566. Combined proceeds were about $218,561; total option exercise cost was about $26,232, implying a gross gain of roughly $192,329 before fees and taxes.

Key Details

• Transaction dates: exercises on 2026-06-04 and 2026-06-05; sales on 2026-06-04 and 2026-06-05. Form filed 2026-06-08.
• Exercise details: 34,976 options exercised at $0.75 per share (options fully vested — footnote F3).
• Sales: total of 34,976 shares sold in open market; weighted average sale prices reported as $6.13 (6/4) and $6.40 (6/5).
• Price ranges (per footnotes): 6/4 sales ranged $6.05–$6.30 (F1); 6/5 sales ranged $6.15–$6.60 (F2). Staff can request a breakdown of shares sold at each price.
• Filing timeliness: Form 4 filed on 2026-06-08 for transactions on 6/4–6/5; no late-filing indication in the provided report.
• Shares owned after the transactions: not specified in the provided filing.

Context

• This was an option exercise followed by immediate open-market sales (a common cashless exercise/liquidity event). The filing shows both the acquisition (exercise) and the disposition of the related derivative positions.
• Options were reported as fully vested (F3). No 10b5-1 plan or other trading-plan language was disclosed in the provided notes.